Aarti Pharmalabs Limited has issued a corrigendum to correct a typographical error in its dividend record date intimation, ensuring accurate regulatory compliance for its dividend declaration.

Corrigendum Details

On February 10, 2026, Aarti Pharmalabs Limited filed a corrigendum with both BSE and National Stock Exchange of India Limited to rectify an error in its dividend record date intimation dated February 09, 2026. The correction specifically addresses a typographical mistake in the mention of the financial year for which the dividend was declared.

Regulatory Filing Information

The corrigendum was submitted to both major stock exchanges where the company's shares are listed. The filing ensures compliance with Regulation 42 requirements for dividend-related communications.

Company Confirmation

Jeevan Mondkar, Company Secretary and Legal Head of Aarti Pharmalabs Limited, confirmed that except for the financial year correction, no other changes were made to the original intimation dated February 09, 2026. The company emphasized that all other details in the dividend record date intimation remain unchanged and valid.

The corrigendum demonstrates the company's commitment to maintaining accurate regulatory filings and ensuring shareholders receive correct information regarding dividend-related matters for Financial Year 2025-26.

Aarti Pharmalabs Limited has completed the allotment of 10,457 equity shares to eligible employees under its Performance Stock Option Plan 2023. The allotment was approved by the company's Nomination and Remuneration Committee during their meeting held on February 09, 2026.

Share Allotment Details

The allotted equity shares carry a face value of Rs. 5 each and were issued pursuant to the exercise of stock options by eligible employees under the Aarti Pharma Performance Stock Option Plan 2023 (PSOP 2023). The allotment complies with the provisions of the Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Updated Share Capital Structure

Following this allotment, Aarti Pharmalabs Limited's paid-up equity share capital has increased significantly. The company's updated capital structure reflects the addition of these employee stock option shares to the existing share base.

The newly allotted equity shares rank pari-passu in all respects with the existing equity shares of the company, ensuring equal rights and privileges for all shareholders.

Regulatory Compliance

The share allotment was conducted under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has informed both BSE Limited (Scrip Code: 543748) and National Stock Exchange of India Limited (Symbol: AARTIPHARM) about this corporate action.

The allotment represents the company's commitment to its employee incentive programs and aligns with regulatory requirements for share-based employee benefits. Company Secretary and Legal Head Jeevan Mondkar signed the regulatory filing, confirming the completion of all necessary procedures for the share allotment process.